The main objective of the present investigation was to formulate and evaluate the aceclofenac nanocapsules for the controlled release of drug to control pain and its associated disease conditions. The nanocapsules of aceclofenac were prepared by deposition of (PLGA) polymer at the O/W interface following acetone displacement from the oily nanodroplets. In this study, different concentrations of PLGA were used (ANC1-ANC5) and selected the best formulation based on its in-vitro drug release profile. The drug content for the aceclofenac nanocapsules varied from 76.8±0.13% to 99.8±0.51%. The entrapment efficiencies were found to be minimum and maximum of 70.99±0.21% and 90.39±0.11%, particle size varied from 210.4±0.23 nm to 325.6±0.62 nm, zeta potential values were in negative and increased from -21.6±0.12 mV to-15.9±0.37 mV. The in-vitro drug release profile of aceclofenac nanocapsules containing 200 mg of PLGA (ANC4) exhibited a desired drug release of 98.41±0.16 at the end of 24 hrs. The study demonstrated the successful preparation of controlled release nanocapsules of aceclofenac.
Loading....